RxTROSPECT DISCOVERY

Integrate drug approval data,
enhance your internal database

Trusted by well
respected companies

Centralize datasets to enhance team capability

centralized knowledge hub

RxTROSPECT is empowering its users to build centralized knowledge platforms to consolidate diverse datasets. By democratizing RxTROSPECT data, our users can get access to our backend data and pull together different datasets into one place, which allows teams to discover valuable knowledge about a disease. It is a powerful offering that allows companies to evolve from a data platform to a knowledge platform

While RxTROSPECT Analytics has been a valuable tool for data analysis, we received a growing demand for access to the underlying raw data that powers our dashboards.

By opening access to RxTROSPECT’s uniquely curated backend data, software engineers and data engineers are given the power to converge separate datasets and make stronger data-driven decisions, uncover hidden insights, and bring innovative therapies to market faster. Companies with business intelligence teams are well-positioned for this option.

Consolidate knowledge,
see new insights

integrated analytics solution

Choose what’s best for you

regional data

Best for small local teams

This base-level option is suitable for companies primarily focused on single region drug development. It equips staff with regional data and associated decisions made by United States or European agencies.

  • Enhance performance of 5 to 9 people with turnkey analytics

  • Rapidly identify regulatory precedent on product approvals

  • Secure login with Multi-Factor Authentication

unlimited data

Best for global teams

Scale-up to 10 users and become eligible for 25 users at no extra cost. The key benefit is it enables global managers to move fast and give staff access without the hassle of doing repetitive procurement.

  • Receive 15 extra users and significantly reduce price per user

  • Give staff access quickly without waiting for procurement

  • Remove the need for Multi-Factor Authentication

*Customers that upgrade their subscription to RxTROSPECT Discovery will automatically keep access to our entry-level offering that is labelled RxTROSPECT Analytics. Access to RxTROSPECT Analytics is expanded to 50 users and includes download / export capability.

GET STARTED

Navigate your optimal approval pathway

Here’s what
people are asking

  • Depending on your company’s procurement process, we can get you access as quickly as we receive a Purchase Order. Your team can expect access within 7 days of receiving a PO.

    The typical steps are:

    1. Customer: Request quote

    2. RxTROSPECT: Send quote

    3. Customer: Create Purchase Order (PO)

    4. RxTROSPECT: Send invoice (with PO # if applicable)

    5. Customer: Provide user details (N/A for renewal)

    6. RxTROSPECT: Give authorized users access to tech

  • Our system is updated within 48 hours of health authority approvals. The scope of our products include the decisions made by the top two global health authorities, the United States FDA and European Medicines Agency.

  • You will receive instructions to create login credentials from our chosen partner, Tableau. Those subscribed to our Base Option are required to use Multi-Factor Authentication (MFA) to login, while those subscribed to our Scaled Option may login directly without the need for MFA.

    Our partnership with Tableau ensures our analytics products are reliably delivered.

rxtrospect analytics

The #1 digital solution for
Digital Regulatory Strategists

This core product offering was purposefully designed with an understanding of the end-user’s role. This means that we get what it means to investigate prior drug approvals in order to inform an optimal approval strategy for a NDA/BLA. Our users appreciate this and their feedback has steered our platform enhancements, which have been continuously improved.

We know what is being asked of the people in regulatory roles and have uniquely built a solution that they value.